ReportsNeuroscience

Spt4 selectively regulates the expression of C9orf72 sense and antisense mutant transcripts

See allHide authors and affiliations

Science  12 Aug 2016:
Vol. 353, Issue 6300, pp. 708-712
DOI: 10.1126/science.aaf7791

Targeting three defects with one strategy

The neurodegenerative diseases amyotrophic lateral sclerosis and frontotemporal dementia are most commonly caused by a mutation in the C9orf72 gene. The mutation is an expanded hexanucleotide repeat in a noncoding region. The expanded repeat produces sense and antisense RNA transcripts, which accumulate in patient cells and appear to sequester RNA-binding proteins. The sense and antisense transcripts are also translated into dipeptide repeat proteins, which are aggregation-prone and accumulate in the brain and spinal cord. Last, loss of function from reduced expression of C9orf72 in neurons and glia could contribute to the disease. Kramer et al. targeted both sense and antisense repeats by blocking a single gene called SPT4, which mitigated degeneration in human cells by reducing all three types of pathologies.

Science, this issue p. 708

Abstract

An expanded hexanucleotide repeat in C9orf72 causes amyotrophic lateral sclerosis and frontotemporal dementia (c9FTD/ALS). Therapeutics are being developed to target RNAs containing the expanded repeat sequence (GGGGCC); however, this approach is complicated by the presence of antisense strand transcription of expanded GGCCCC repeats. We found that targeting the transcription elongation factor Spt4 selectively decreased production of both sense and antisense expanded transcripts, as well as their translated dipeptide repeat (DPR) products, and also mitigated degeneration in animal models. Knockdown of SUPT4H1, the human Spt4 ortholog, similarly decreased production of sense and antisense RNA foci, as well as DPR proteins, in patient cells. Therapeutic targeting of a single factor to eliminate c9FTD/ALS pathological features offers advantages over approaches that require targeting sense and antisense repeats separately.

Amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) are devastating neurodegenerative diseases. The C9orf72 mutation (1, 2) is a common cause of both ALS and FTD (c9FTD/ALS), and intense efforts are exploring disease mechanisms and developing therapeutic strategies (3, 4). The C9orf72 gene harbors a hexanucleotide repeat, GGGGCC, located in the first intron. In c9FTD/ALS patients, this hexanucleotide repeat tract is expanded to hundreds or even thousands of repeats. Several hypotheses have emerged to explain how C9orf72 mutations cause neurodegeneration. RNAs transcribed from the GGGGCC repeats that accumulate as foci in the nucleus and cytoplasm could cause disease by sequestering RNA-binding proteins and splicing factors via an RNA toxicity mechanism (57). The transcribed nucleotide repeats are also substrates for an unconventional form of translation, termed repeat-associated non-ATG (RAN) translation (810). The resulting dipeptide repeat (DPR) proteins could cause disease through proteotoxic mechanisms (11). Lastly, the expanded repeats reduce C9orf72 mRNA expression (12, 13), which may cause a loss of C9orf72 function. A therapeutic approach that uses antisense oligonucleotides (ASOs) to target GGGGCC repeat–containing RNA transcripts for degradation is being pursued (5, 14, 15). However, RNA foci containing GGCCCC repeats transcribed in the antisense direction also accumulate abundantly in c9FTD/ALS (14, 16). Thus, it will be important to consider strategies that target both sense and antisense repeat–containing RNAs.

Spt4 is a highly conserved transcription elongation factor that, together with its binding partner Spt5, regulates RNA polymerase II processivity (1720). A recent genetic screen in yeast revealed that mutation of Spt4 selectively reduced the transcription of long CAG trinucleotide repeats associated with Huntington’s disease (21). Inhibiting the mammalian ortholog of Spt4, SUPT4H1, also decreased production of expanded CAG-derived polyQ aggregates in murine striatal neurons. Notably, lowering levels of Spt4 did not affect expression of proteins containing short CAG repeat regions. Moreover, RNA-sequencing (RNA-seq) analysis found only a limited effect of SPT4 deletion on normal gene expression throughout the transcriptome (21). Thus, Spt4 acts as a specialized transcription factor selectively required for the expression of long trinucleotide repeat–containing transcripts.

Because Spt4 inhibition lowers the expression of disease-associated trinucleotide repeat expansions (21), we hypothesized that Spt4 inhibition might reduce expression of expanded sense and antisense hexanucleotide repeats in mutant C9orf72. If so, it could overcome the current hurdles of designing and optimizing two strategies to target sense and antisense repeats separately. To address this hypothesis, we began by testing the effect of SPT4 deletion in yeast (Saccharomyces cerevisiae) expressing C9orf72 hexanucleotide repeats. We transformed wild-type (WT) yeast cells with a galactose-inducible expression construct harboring either short (2) or expanded (66) sense GGGGCC repeats or antisense GGCCCC repeats lacking an ATG start codon. Although yeast expressing expanded sense or antisense repeats formed cytoplasmic and perinuclear RNA foci, neither the short nor the expanded repeat constructs were toxic, as assessed by serial dilution growth analysis of yeast strains (fig. S1, A to D). Using quantitative reverse transcription–polymerase chain reaction (qRT-PCR), we next evaluated the effect of SPT4 deletion (spt4Δ) on transcription of sense and antisense repeats. Whereas spt4Δ had no effect on short, nonexpanded repeats, we observed a significant decrease in expression of (GGGGCC)66 or (GGCCCC)66 transcripts in spt4Δ cells relative to WT (Fig. 1A). Moreover, SPT4 deletion completely blocked RNA foci formation in yeast expressing (GGGGCC)66 or (GGCCCC)66 (Fig. 1, B to D). Expressing Spt4 from a plasmid in spt4Δ cells restored sense and antisense RNA foci formation (Fig. 1, B to D), confirming the requirement of Spt4 for the production of transcripts containing expanded C9orf72 repeats and the subsequent accumulation of these RNA transcripts into foci.

Fig. 1 Spt4 is required for C9orf72 mutant strand transcription, RNA foci formation, and RAN translation in S. cerevisiae.

Yeast were transformed with plasmids expressing sense (GGGGCC)n or antisense (GGCCCC)n C9orf72 repeats of varying lengths (2R or 66R) but lacking ATG translation start codons under the control of a galactose-inducible promoter. (A) qRT-PCR analysis of C9-repeat RNA levels in WT and spt4Δ yeast after 6-hour galactose inductions. C9-repeat RNA levels were normalized to levels of yeast actin, then quantified relative to WT yeast (two-tailed unpaired t tests, ****P < 0.0001, ***P < 0.001; n.s., not significant). Data expressed as relative fold changes, spt4Δ/WT [one-way analysis of variance (ANOVA) with Dunnett’s multiple comparisons test, **P < 0.01]. (B) Sense and antisense RNA foci were detected by fluorescence in situ hybridization (FISH). Percentages of yeast cells containing sense (C) and antisense (D) foci were quantified across genotypes [blue, 4′,6-diamidino-2-phenylindole (DAPI); red, C9-repeat LNA probe; one-way ANOVA with Dunnett’s multiple comparisons test, ****P < 0.0001, *P < 0.05; n.s., not significant; n.d., not determined]. (E) Sandwich immunoassay detection of RAN-translated poly(GP) in WT and spt4Δ yeast (two-tailed unpaired t test ****P < 0.0001).

In addition to RNA foci, another pathological feature of c9FTD/ALS is the presence of DPR proteins produced by RAN translation (8, 9, 22). To investigate whether RAN translation occurs in yeast expressing expanded GGGGCC repeats, we used an immunoassay to detect expression of a DPR protein produced from the glycine-proline (GP) reading frame. Poly(GP) was not detected in lysates of yeast cells expressing 2 or 66 GGGGCC repeats from a low-copy (CEN) expression plasmid; however, robust poly(GP) expression was observed in lysates of yeast cells in which 40 GGGGCC repeats were expressed at higher levels from a high-copy (2-μm) expression plasmid (Fig. 1E and fig. S1C). These data are consistent with the prior finding that the abundance of poly(GP) proteins correlates with levels of repeat-containing transcripts (11, 12). Notably, deleting SPT4 in (GGGGCC)40-expressing yeast significantly decreased levels of RAN-translated poly(GP) (Fig. 1E). This effect was specific to the expanded nucleotide repeat construct (as in Fig. 1A), because SPT4 deletion did not suppress toxicity of three non–repeat-containing disease-associated proteins [TDP-43, FUS/TLS, and poly(PR)] (fig. S2A). Further, SPT4 deletion did not affect expression of green fluorescent protein under the control of the same galactose-inducible promoter or expression of the endogenous yeast glyceraldehyde-3-phosphate dehydrogenase (GAPDH) protein (fig. S2B). Thus, two key components of c9FTD/ALS pathology (RNA foci and DPR proteins) are recapitulated in yeast models and are mitigated by Spt4 depletion.

We next tested the effect of modulating Spt4 levels in vivo using animal models. Using the synaptobrevin (snb-1) promoter to drive neuronal expression of (GGGGCC)66 (fig. S3A), we developed a nematode (Caenorhabditis elegans) model of the C9orf72 repeat expansion characterized by RNA foci formation (Fig. 2A and fig. S3, B and C), DPR protein production (Fig. 2C), and a significant reduction in life span (Fig. 2D and fig. S3G). To determine the effect of altered Spt4/SUPT4H1 expression levels, we crossed (GGGGCC)66-expressing worms to worms expressing human SUPT4H1 also driven by the snb-1 promoter (Fig. 2, A to D, and fig. S3, D to F) or fed RNAi to knock down endogenous Spt4 (Fig. 2, E to H). We observed an increase in GGGGCC repeat RNA and poly(GP) expression, as well as enhanced toxicity in (GGGGCC)66 worms in the presence of exogenous SUPT4H1 (Fig. 2, B to D, and fig. S3, E to G). Conversely, reduction in endogenous Spt4 levels decreased both GGGGCC repeat RNA and poly(GP) levels and also improved the survival of (GGGGCC)66 worms (Fig. 2, E to H, and fig. S3G). Similar modulation of toxicity was observed in transgenic Drosophila engineered to express 6, 29, or 49 pure GGGGCC repeats under the control of the gmr-GAL4 driver. Consistent with previous reports (2226), expression of (GGGGCC)49 caused severe eye degeneration (Fig. 2I and fig. S4), whereas the shorter expanded repeat, (GGGGCC)29, caused a mild phenotype with a modest disruption of the external eye and significant thinning of the retinal ganglia. The unexpanded repeat (GGGGCC)6 caused no observable effect in the retina. Spt4 RNAi partially suppressed the degenerative phenotype of the external and internal eye in (GGGGCC)49-expressing flies and almost completely suppressed the retinal thinning normally observed in (GGGGCC)29-expressing flies (Fig. 2J and fig. S4, B to D). As in yeast, the effect of Spt4 depletion was specific to expression of expanded GGGGCC repeats because the expression of a control β-galactosidase transgene was unaffected (fig. S4E). Furthermore, reducing the expression of Spt4 significantly increased the life span of adult flies ubiquitously expressing (GGGGCC)49 repeats (Fig. 2K). Thus, the level of Spt4 expression influences the pathogenicity of C9orf72 GGGGCC repeats in the nervous systems of both C. elegans and Drosophila.

Fig. 2 Spt4 modulation influences pathogenicity of GGGGCC repeats in C. elegans and mitigates neurodegeneration in a Drosophila model of c9FTD/ALS.

(A) RNA FISH reveals GGGGCC RNA foci formation (red) in normal (N2) worms, (GGGGCC)66-expressing worms (C9 66R), and worms expressing both (GGGGCC)66 and human SUPT4H1 (C9 66R × SUPT4H1). The intestinal marker (green) denotes the presence of the (GGGGCC)66 transgene, and DAPI (blue) indicates labeled nuclei (scale bar: low magnification 50 μm, high magnification 5 μm). (B and C) Expression of GGGGCC RNA levels quantified by qPCR relative to levels in (GGGGCC)66-expressing worms (two-tailed unpaired t test, ****P < 0.0001) (B) and poly(GP) levels quantified by immunoassay (two-tailed unpaired t test, ****P < 0.0001) (C). (D) A life-span assay assessed the impact of (GGGGCC)66 and/or SUPT4H1 overexpression on survival (N2 n = 145 worms, C9 66R n = 160, C9 66R × SUPT4H1 n = 122, SUPT4H1 n = 144; log-rank (Mantel-Cox) test, ****P < 0.0001; n.s., not significant. See also fig. S3G). (E to H) qPCR measured GGGGCC (E) and Spt4 mRNA (F) levels in (GGGGCC)66-expressing worms fed control (OP50) or RNAi targeting Spt4 (two-tailed unpaired t test, ****P < 0.0001). (G) An immunoassay revealed the percentage change in poly(GP) levels after RNAi-mediated reduction in Spt4 expression (two-tailed unpaired t test, ****P < 0.0001). (H) Spt4 RNAi improved survival in (GGGGCC)66 worms (OP50 n = 119 worms, RNAi Spt4 n = 120; log-rank (Mantel-Cox) test, ****P < 0.0001. See also fig. S3G). (I and J) External and internal retinal structures of normal flies or flies expressing (GGGGCC)n transgenes, with coexpression of (I) a control (luciferase) shRNA or (J) Spt4 shRNA. A gmr-GAL4 eye-specific driver was used to express UAS-transgenes. (I) Control animals with driver alone (w1118) or a short GGGGCC repeat (GGGGCC)6 have normal eye structure. Animals expressing GGGGCC29 show a mild disruption to the highly precise external ommatidial structure (arrows), and thinning and gaps in the internal retina, whereas animals expressing GGGGCC49 have severely degenerate tissue both externally and internally. (J) Reduction in Spt4 has no effect on normal or GGGGCC6-expressing animals and resulted in reduced toxicity in both the external and internal retinal structures of flies bearing 29 or 49 GGGGCC repeats. (K) Reducing the expression of Spt4 in (GGGGCC)49 animals increased the life expectancy for animals expressing transgenes using a ubiquitous, drug-inducible driver, da-GS. Expression was induced in adult animals to avoid effects of expressing transgenes during development. Expression of the control (luciferase) shRNA or Spt4 shRNA had no effect on the life span over this time frame when expressed alone (curves superimposed). Statistical analysis was done using a log-ranked test comparing (GGGGCC)49 animals expressing the control shRNA versus the Spt4 shRNA.

The experiments in yeast, nematodes, and flies are consistent with a role for Spt4 in regulating expression of C9orf72 hexanucleotide repeat expansions. These experiments all relied on expression of GGGGCC or GGCCCC repeats from plasmids or transgenes. To extend our findings, we tested the ability of SUPT4H1 to regulate expression of endogenous C9orf72 repeats in cells obtained from humans afflicted with ALS. We first analyzed cultured fibroblast cells derived from healthy subjects or from ALS patients with or without C9orf72 repeat expansions (fig. S5A). Foci of sense and antisense repeat–containing RNA (fig. S5B) and poly(GP) proteins (fig. S5C) were selectively detected in c9ALS fibroblasts. Consistent with previous findings in brain tissues from c9FTD/ALS patients (11), the abundance of poly(GP) proteins correlated with mRNA levels of C9orf72 variant 3 (fig. S5G) but not of variant 1, variant 2, or total C9orf72 mRNA (fig. S5, D to F) or with repeat length (fig. S5H).

Having established the occurrence of RAN translation and RNA foci formation in c9ALS fibroblasts, we evaluated whether depletion of SUPT4H1 and/or its binding partner, SUPT5H, mitigates these pathological hallmarks. Treating cultured fibroblasts from three c9ALS patients with small interfering RNAs (siRNAs) against SUPT4H1 and SUPT5H (siSUPT4H1, and siSUPT5H, respectively) simultaneously decreased both SUPT4H1 and SUPT5H mRNA and protein levels (Fig. 3, A and B). Exposing fibroblasts to siSUPT4H1 alone significantly decreased SUPT4H1 mRNA and protein expression and also caused statistically significant, albeit less drastic, decreases in SUPT5H abundance (Fig. 3, A and B). Upon treatment of c9ALS fibroblasts with siSUPT5H alone, we observed the predicted reductions in SUPT5H mRNA and protein. Depletion of SUPT5H also led to a significant decrease in SUPT4H1 protein abundance, although it had little effect on SUPT4H1 mRNA (Fig. 3, A and B).

Fig. 3 Reduction of SUPT4H1 or SUPT5H in c9ALS fibroblasts inhibits production of C9orf72 variant 3 mRNA, sense and antisense RNA foci, and DPR proteins.

Cultured fibroblasts from three c9ALS patients were treated with a control siRNA (siCtrl), siRNA(s) directed against SUPT4H1 and/or SUPT5H (siSUPT4H1 and siSUPT5H, respectively), or a C9orf72-repeat targeting ASO (C9-ASO) for 10 days. After treatment, mRNA levels of SUPT4H1 and SUPT5H were determined by qPCR (A), and SUPT4H1 and SUPT5H protein expression was examined by immunoblot followed by densitometric quantification (B). (C) The effect of SUPT4H1 and/or SUPT5H depletion on C9orf72 variant 3 mRNA expression and poly(GP) protein levels was examined by qPCR and immunoassay, respectively. (D) RNA FISH with probes for GGGGCC or GGCCCC RNA was used to detect foci containing sense or antisense repeats (red) in the nucleus of cells (blue, Hoechst 33258). The percentage of cells containing foci was then determined. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001 as assessed by one-way ANOVA followed by Tukey’s post-hoc analysis. Scale bar: 5 μm.

Reduction of SUPT4H1 and/or SUPT5H abundance significantly decreased levels of C9orf72 variant 3 mRNA and poly(GP) proteins, as well as foci formed of sense or antisense repeat RNA in c9ALS fibroblasts, but did not lead to any overt toxicity (Fig. 3, C and D, and figs. S6 and S7). In contrast, treatment of c9ALS fibroblasts with an ASO targeting the C9orf72 sense transcript mitigated most of these features, with the key exception that foci formed of antisense GGCCCC-containing transcripts remained unaffected (Fig. 3, C and D). Thus, lowering the abundance of a single gene product, SUPT4H1 or SUPT5H, decreased all three of the major pathological features of c9FTD/ALS: sense RNA foci, antisense RNA foci, and DPR proteins. Intriguingly, SUPT4H1 and SUPT5H mRNA expression levels positively correlated with levels of C9orf72 variant 3 mRNA (Fig. 4A) or poly(GP) proteins (Fig. 4B) in the cerebellum of human C9orf72 repeat expansion carriers. Partial reduction in SUPT4H1 abundance by lentiviral short hairpin RNA (shRNA) in 8-week-old cortical neurons differentiated from four independent lines of human-induced pluripotent stem cells from c9FTD/ALS patients (13, 15) (Fig. 4, C to E) resulted in decreased levels of C9orf72 variant 3 mRNA (Fig. 4D) and poly(GP) proteins (Fig. 4E). To address whether there were global transcriptional changes upon depletion of SUPT4H1, we performed RNA sequencing on two human fibroblast lines treated with SUPT4H1 siRNA. As predicted by RNA-sequencing experiments in yeast and mouse (21), we found only a small subset of human genes that were differentially expressed after SUPT4H1 knockdown (fig. S8), indicating that knockdown of SUPT4H1 affects expanded repeat transcripts but has a minimal impact on other transcripts.

Fig. 4 Pathological features of c9FTD/ALS correlate with SUPT4H1 and SUPT5H expression in patient brain tissue, and partial knockdown of SUPT4H1 in C9orf72 iPSC-derived cortical neurons reduces production of C9orf72 variant 3 mRNA and DPR proteins.

(A and B) SUPT4H1 and SUPT5H mRNA levels in cerebellar tissue from c9FTD/ALS patients were measured by qPCR and found to associate with cerebellar levels of C9orf72 variant 3 mRNA measured by qPCR (A) and with poly(GP) proteins measured by immunoassay (B) using a Spearman’s test of correlation. (C to E) Cortical neurons differentiated from each C9orf72 iPSC line were aged for 8 weeks and then transduced with lentivirus expressing either a noncoding control shRNA or an shRNA against SUPT4H1 mRNA for 6 days. Four iPSC lines derived from three patients with C9orf72 repeat expansions were used. Knockdown of SUPT4H1 mRNA (C) and C9orf72 variant 3 mRNA expression levels (D) were determined by qPCR. Poly(GP) protein levels were examined by immunoassay (E). *P < 0.05, **P < 0.01, ****P < 0.0001 as assessed by two-tailed unpaired t test from three independent neuronal differentiations.

Here, we found that the transcription factor Spt4/SUPT4H1 is required for the specific expression of hexanucleotide repeat expansions in the C9orf72 gene. Previous studies have shown that injection of ASOs targeting SUPT4H1 expression or genetic reduction in Supt4h levels in mouse models of Huntington’s disease resulted in a mutant allele–specific reduction in huntingtin mRNA and protein abundance (27). This treatment reduced the amount of polyQ aggregates, delayed motor impairment, and prolonged survival (27). Our data suggest that similar strategies aimed at diminishing the function of SUPT4H1, such as ASOs or small molecules, could be pursued as an effective therapy for c9FTD/ALS.

Supplementary Materials

www.sciencemag.org/content/353/6300/708/suppl/DC1

Materials and Methods

Figs. S1 to S8

Table S1

References (2840)

Data File S1

References and Notes

Acknowledgments: We thank D. Cerza and Y. Zu for technical support. This work was supported by NIH grants R01NS065317 (A.D.G.), R01NS09386501 (A.D.G., L.P.), R01NS073660 (A.D.G., N.M.B.), R01AG026251 (L.P.), R21NS079807 (Y.-J.Z.), R21NS094489 (C.N.C.), R01NS063964 (L.P.), R01NS077402 (L.P.), R21NS084528 (L.P.), P01NS084974 (L.P.), R01NS088689 (L.P.), R01ES20395 (L.P.), R01NS085812 (S.N.C. and T.-H.C.), R01NS079725 (F.-B.G.), Mayo Clinic Foundation (L.P.), Alzheimer’s Association [NIRP-14-304425 (Y.-J.Z.)], Amyotrophic Lateral Sclerosis Association (Y.-J.Z, T.F.G., M.P., L.P., F.-B.G.), the National Science Foundation Graduate Research Fellowship (N.J.K.), the Robert Packard Center for ALS Research at Johns Hopkins (L.P., A.D.G., F.B.-G.), Target ALS (L.P., A.D.G., N.B., F.-B.G.), Association for Frontotemporal Degeneration (S.A.), Stanford University (S.N.C.), and the Glenn Foundation (A.D.G., N.M.B). The induced pluripotent stem cell (iPSC) lines are available from the Gao laboratory under a material transfer agreement with the University of Massachusetts Medical School. R.C.P. has paid consulting relationships with Hoffmann–La Roche, Inc.; Merck, Inc.; Genentech, Inc.; Biogen, Inc.; and Eli Lilly & Co. RNA sequencing data are deposited with the National Center for Biotechnology Information Gene Expression Omnibus (GSE83484).
View Abstract

Navigate This Article